Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home

Gardulf, Ann; Nicolay, Uwe; Asensio, Òscar; Bernatowska, Ewa; Böck, Andreas; Costa‐Carvalho, Beatriz Tavares; Granert, Carl; Haag, Stefan; Hernández, Dolores; Kiessling, Peter; Kuś, Jan; Matamoros, N.; Niehues, Tim; Schmidt, Sigune; Schulze, Ilka; Borte, Michael

doi:10.1016/j.jaci.2004.06.053

Cited by 238 publications

(228 citation statements)

References 18 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…We only observed local adverse reactions over the abdomen a few times in some of the cases at the beginning of the treatment, as reported in the literature (8)(9)(10)(11)17); otherwise there was no systemic complications. Local reactions including urticaria, swelling, redness and burning sensation at the infusion site as seen in case 1 and case 3 (Figure 2, 3) were encountered.…”

Section: Discussionsupporting

confidence: 71%

“…Some published studies suggested that each PID patient requires personal immunoglobulin levels to prevent breakthrough infections and therefore our case might need SCIG dose adjustment to prevent infections (13). Gardulf et al reported that SCIG home therapy ensured better health, improved social/school functioning, reduced emotional stress and limitations on personal time for parents, and created fewer limitations on family activities (8). In our cases the most dramatic change was seen in Case 1.…”

Section: Discussionmentioning

confidence: 67%

“…Recently, immunoglobulin treatment via the subcutaneous route have became popular and preferable method. Advantages of SCIG include greater independence, no need for vascular access; decreased systemic side effects and more stable serum IgG levels (8)(9)(10). Disadvantages include requiring frequent dosing and limitation of the volume that can be administered (11)(12)(13).…”

Section: Discussionmentioning

confidence: 99%

“…Until now there have been no discontinuations because of tolerability problems. Unlike IVIG, there are very few systemic adverse effects with SCIG in published studies (8)(9)(10)(11). As reported in other studies, we reported only mild local adverse reactions (Figure 2, 3).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Subcutaneous Immunoglobulin Replacement Therapy Experience with Intravenous Preparation

Özdemir¹

2018

Asthma Allergy Immunol

View full text Add to dashboard Cite

ÖZAmaç: İntravenöz immünoglobulin preparatları primer immünyetmezlik tedavisinde uzun yıllardır kullanılmaktadır. Son zamanlarda, subkutanöz yolla immünoglobulin verilimi ön plana çıkmıştır. Subkutan yolla verilen immünoglobulin daha stabil serum immünoglobulin düzeyleri sağlar ve sistemik yan etki sıklığı intravenöz yola göre daha düşüktür. Hastanın kendisinin ya da ebeveyninin evde bu metotu uygulayabilmesi yaşam kalitesini artırır. Subkutanöz verilim için üretilen immünoglobulin preparatları Avrupa ve ABD'de 2006'dan beri mevcuttur. Subkutan immünoglobulin preparatlarının Türkiye'de bulunmamasına rağmen, yakın zamanda %10 konsantrasyonundaki üç değişik intravevöz ürününün kullanım talimatına subkutan kullanım yolu eklenmiştir. Amacımız, bu intravenöz immünoglobulin preparatlarından birini subkutan yolla kullanmak ve bu uygulamanın avantaj ve dezavantajlarını ortaya koymaktır. Gereç ve Yöntem: Kliniğimizden yapılacak işlem anlatılmış ve onamları alınmış altı primer immünyetmezlik hastası seçilmiştir. Bu hastalar, son bir kaç yıldır intravenöz immünoglobulin ile tedavi edilmektedir. Bu hastaların aylık immünoglobulin dozları hesaplanıp yaklaşık olarak haftalık dozlara bölündü. İlk bir kaç uygulama hastalar ve/veya aileleri işlemi öğrenene kadar tıbbi gözetim altında hastanede gerçekleştirilmiştir. Bulgular: Küçük hasta örneğimizde daha az yan etki, daha iyi yaşam kalitesi ve daha az enfeksiyon oranları ile sonuçlar umut verici olmuştur. Sonuç: Makalede, intravenöz immünoglobulin preparatını başarıyle subkutan yolla kullandığımız kliniğimizin 6 primer immünyetmezlik hastası üzerindeki deneyimimizi anlatmaktayız . ABSTRACTObjective: Intravenous immunoglobulin preparations have been used in the treatment of primary immunodeficiency for many years. Recently, immunoglobulin administration via the subcutaneous route has become popular. Subcutaneously administered immunoglobulin provides more stable serum immunoglobulin levels and has a lower incidence of systemic adverse effects than the intravenous route. This method increases the quality of the patient's life by self administration or parental administration at home. Immunoglobulin preparations designed for subcutaneous administration have been available in Europe and the US since 2006. Although subcutaneous immunoglobulin preparations are not available in Turkey, the subcutaneous administration route has recently been included in the instructions of the three intravenous products with 10% concentration. Our aim was to use one of these intravenous immunoglobulin preparations via the subcutaneous route and describe its advantages and disadvantages. Materials and Methods: Six primary immunodeficiency patients were selected from our clinic. The procedure was described and informed consent obtained. They had been treated with intravenous immunoglobulin for the last few years. Their monthly immunoglobulin dosage was calculated and roughly divided into weekly doses. The first few administrations took place under medical supervision at the hospital until the patients and/...

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Subcutaneous Immunoglobulin Replacement Therapy Experience with Intravenous Preparation

Özdemir¹

2018

Asthma Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Subcutaneous immunoglobulins (SCIg) have been shown to be safe, cost-effective and greatly appreciated in terms of health-related quality of life (HRQL) [17][18][19][20][21][22] in patients with primary immunodeficiencies (e.g. common variable immunodeficiency).…”

Section: Introductionmentioning

confidence: 99%